Echo Therapeutics Announces Multiple Patents and Trademark Grants
PHILADELPHIA, Aug. 8, 2011 /PRNewswire/ — Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced the receipt of notices of issuance for two patents covering its Symphony tCGM System and notices of registration for the trademarks PRELUDE and SYMPHONY.
Echo Therapeutics received notice that its patent application entitled, “System and Method for Continuous Non-Invasive Glucose Monitoring” will issue as U.S. Patent No. 7,963,917. As a result of a patent term adjustment that is expected to add nearly 4 years to the term of the patent, it is expected to expire in 2025. Echo Therapeutics also received notice that its patent application entitled “Transdermal Analyte for Monitoring Systems and Methods for Analyte Detection” was issued as South Africa Patent No. 2009/06959 and will expire in 2028. Additionally, Echo has received notice that its applications for the trademark PRELUDE have been registered for use in International Class 10 in South Korea and Mexico; and its application for the trademark SYMPHONY has been registered for use in International Class 10 in Israel.
“We have long recognized the unique value that our non-invasive, glucose monitoring technology can provide, and these patents reinforce this belief, further demonstrating the proprietary nature of our technology,” stated Patrick Mooney, M.D., Echo’s Chairman and CEO. “We believe that our intellectual property portfolio will provide our products with long-term market protection and will add significantly to our shareholder value.”
These patents join eleven U.S. patents and twenty-eight foreign patents already obtained by Echo Therapeutics. Over 40 patent applications by Echo are pending in the U.S. and foreign countries.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s and its partners’ ongoing studies, including the efficacy of Echo’s Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo’s Symphony tCGM and Prelude SkinPrep Systems, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Director, Corporate Communications
SOURCE Echo Therapeutics, Inc.